{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:14:18Z","timestamp":1788545658972,"version":"build-2803163510"},"reference-count":75,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"36","funder":[{"DOI":"10.13039\/100032339","name":"BioNTech","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100032339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Adv."],"published-print":{"date-parts":[[2026,9,4]]},"abstract":"<jats:p>\n                    The therapeutic potential of interleukin-2 (IL-2) in cancer treatment is limited by toxicity challenges, partly due to an unfavorable pharmacokinetic profile and unintended activation of regulatory T (T\n                    <jats:sub>reg<\/jats:sub>\n                    ) cells alongside the desired activation of CD8\n                    <jats:sup>+<\/jats:sup>\n                    effector T cells. To selectively stimulate CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells over T\n                    <jats:sub>reg<\/jats:sub>\n                    cells, we engineered an IL-2 variant (IL-2var) with a dual-tuned affinity profile that features reduced binding to IL-2R\u03b1 (CD25) and enhanced binding to IL-2R\u03b2 (CD122). To optimize its pharmacokinetics and facilitate tumor enrichment, the variant is fused to albumin and delivered as an mRNA encapsulated in a lipid nanoparticle (Alb\u2013IL-2var RNA-LNP), enabling sustained systemic exposure from hepatic production upon intravenous administration. We show that Alb\u2013IL-2var has a favorable pharmacokinetic profile and is tolerated at biologically active doses in immunocompetent mice and cynomolgus monkeys. Selective enhancement of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses over T\n                    <jats:sub>reg<\/jats:sub>\n                    cells is demonstrated in vitro in human peripheral blood mononuclear cells and in vivo in mice and cynomolgus monkeys. When combined with an mRNA cancer vaccine in syngeneic subcutaneous mouse tumor models, Alb\u2013IL-2var RNA-LNP stimulates the expansion of tumor-infiltrating and circulating tumor antigen\u2013specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, but not T\n                    <jats:sub>reg<\/jats:sub>\n                    cells. In advanced and cold syngeneic tumor models, it enhances the efficacy of radiotherapy, checkpoint inhibitors, and cancer vaccines. Combination with checkpoint inhibitors and vaccine induces profound proinflammatory conversion of cold tumors. These preclinical results validate a rational design approach to overcome the limitations of IL-2 therapy and support the clinical evaluation of Alb\u2013IL-2var RNA-LNP for solid cancers.\n                  <\/jats:p>","DOI":"10.1126\/sciadv.aeh9215","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:58:46Z","timestamp":1788544726000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Messenger RNA delivery of a dual CD25\/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity"],"prefix":"10.1126","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7788-3380","authenticated-orcid":true,"given":"Mathias","family":"Vormehr","sequence":"first","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1943-3431","authenticated-orcid":true,"given":"Lena M.","family":"Kranz","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4561-2273","authenticated-orcid":true,"given":"Alexander","family":"Muik","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0402-751X","authenticated-orcid":true,"given":"Sina","family":"Fellermeier-Kopf","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0379-1915","authenticated-orcid":true,"given":"Jan D.","family":"Beck","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eisel","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8097-593X","authenticated-orcid":true,"given":"Nadja","family":"Salomon","sequence":"additional","affiliation":[{"name":"TRON gGmbH \u2013 Translational Oncology at the University Medical Center of the Johannes Gutenberg University, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-5075","authenticated-orcid":true,"given":"Bonny Gaby","family":"Lui","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Diekmann","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"T\u00fcreci","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."},{"name":"HI-TRON \u2013 Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz) of the DKFZ, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0363-1564","authenticated-orcid":true,"given":"Ugur","family":"Sahin","sequence":"additional","affiliation":[{"name":"BioNTech SE, Mainz, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1382472"},{"key":"e_1_3_2_3_2","first-page":"S76","article-title":"The future of interleukin-2: Enhancing therapeutic anticancer vaccines","volume":"6","author":"Overwijk W. W.","year":"2000","unstructured":"W. W. Overwijk, M. R. Theoret, N. P. Restifo, The future of interleukin-2: Enhancing therapeutic anticancer vaccines. Cancer J. Sci. Am. 6, S76\u2013S80 (2000).","journal-title":"Cancer J. Sci. Am."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002139"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.122"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott D. F.","year":"2005","unstructured":"D. F. McDermott, M. M. Regan, J. I. Clark, L. E. Flaherty, G. R. Weiss, T. F. Logan, J. M. Kirkwood, M. S. Gordon, J. A. Sosman, M. S. Ernstoff, C. P. Tretter, W. J. Urba, J. W. Smith, K. A. Margolin, J. W. Mier, J. A. Gollob, J. P. Dutcher, M. B. Atkins, Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133\u2013141 (2005).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_7_2","first-page":"79","article-title":"Update on use of aldesleukin for treatment of high-risk metastatic melanoma","volume":"4","author":"Amaria R. N.","year":"2015","unstructured":"R. N. Amaria, A. Reuben, Z. A. Cooper, J. A. Wargo, Update on use of aldesleukin for treatment of high-risk metastatic melanoma. Immunotargets Ther. 4, 79\u201389 (2015).","journal-title":"Immunotargets Ther."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00455-z"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher J. P.","year":"2014","unstructured":"J. P. Dutcher, D. J. Schwartzentruber, H. L. Kaufman, S. S. Agarwala, A. A. Tarhini, J. N. Lowder, M. B. Atkins, High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J. Immunother. Cancer 2, 26 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(97)00041-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511161103"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.11.010"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1536"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10975"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag3187"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201895"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1038\/s41598-022-09278-7","article-title":"Efficacy and antitumor activity of a mutant type of interleukin 2","volume":"12","author":"Dehghan R.","year":"2022","unstructured":"R. Dehghan, A. Beig Parikhani, S. Zeinali, M. Shokrgozar, A. Amanzadeh, S. Ajdary, R. Ahangari Cohan, Y. Talebkhan, M. Behdani, Efficacy and antitumor activity of a mutant type of interleukin 2. Sci. Rep. 12, 5376 (2022).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003155"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/81199"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi050436x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI95914"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"22966","DOI":"10.1038\/s41598-021-02449-y","article-title":"Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity","volume":"11","author":"Song D.","year":"2021","unstructured":"D. Song, X. Liu, C. Dong, Q. Wang, C. Sha, C. Liu, Z. Ning, J. Han, H. Liu, M. Zong, Y. Zhao, Y. Li, G. Liu, X. Shao, C. Dou, Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity. Sci. Rep. 11, 22966 (2021).","journal-title":"Sci. Rep."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0701"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.013"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4","article-title":"Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma","volume":"77","author":"Legha S. S.","year":"1996","unstructured":"S. S. Legha, M. A. Gianan, C. Plager, O. E. Eton, N. E. Papadopoulous, Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 77, 89\u201396 (1996).","journal-title":"Cancer"},{"key":"e_1_3_2_27_2","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura Y.","year":"1986","unstructured":"Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387\u20136392 (1986).","journal-title":"Cancer Res."},{"key":"e_1_3_2_28_2","unstructured":"C. K. Garcia S. Mitra L. J. Warren A. M. Ring Superagonists partial agonists and antagonists of interleukin-2. Patent no. EP 3134102 B1 (2019)."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012863"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature18300"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14426"},{"key":"e_1_3_2_32_2","first-page":"e1629259","article-title":"HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory","volume":"8","author":"Grunwitz C.","year":"2019","unstructured":"C. Grunwitz, N. Salomon, F. Vascotto, A. Selmi, T. Bukur, M. Diken, S. Kreiter, O. Tureci, U. Sahin, HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Onco. Targets Ther. 8, e1629259 (2019).","journal-title":"Onco. Targets Ther."},{"key":"e_1_3_2_33_2","first-page":"1771925","article-title":"A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice","volume":"9","author":"Salomon N.","year":"2020","unstructured":"N. Salomon, F. Vascotto, A. Selmi, M. Vormehr, J. Quinkhardt, T. Bukur, B. Schrors, M. Loewer, M. Diken, O. Tureci, U. Sahin, S. Kreiter, A liposomal RNA vaccine inducing neoantigen-specific CD4+ T cells augments the antitumor activity of local radiotherapy in mice. Onco. Targets Ther. 9, 1771925 (2020).","journal-title":"Onco. Targets Ther."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03334-7"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.015"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1325-x"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1324-y"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0114"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI25591"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05257-0"},{"key":"e_1_3_2_44_2","first-page":"1309","article-title":"IL-2Ralpha-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Wu W.","year":"2023","unstructured":"W. Wu, T. Chia, J. Lu, X. Li, J. Guan, Y. Li, F. Fu, S. Zhou, Y. Feng, J. Deng, J. Zou, J. Sun, Y. Yao, X. Ling, Z. Wu, Y. Zhang, J. Xu, F. Wang, X. Liang, M. Wu, H. Liu, B. Chen, K. He, IL-2Ralpha-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat Cancer 4, 1309\u20131325 (2023).","journal-title":"Nat Cancer"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1102282"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001"},{"key":"e_1_3_2_47_2","first-page":"1673125","article-title":"Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer","volume":"9","author":"Hos B. J.","year":"2019","unstructured":"B. J. Hos, M. G. M. Camps, J. van den Bulk, E. Tondini, T. C. van den Ende, D. Ruano, K. Franken, G. M. C. Janssen, A. Ru, D. V. Filippov, R. Arens, P. A. van Veelen, N. Miranda, F. Ossendorp, Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer. Onco. Targets Ther. 9, 1673125 (2019).","journal-title":"Onco. Targets Ther."},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"100108","DOI":"10.1016\/j.mcpro.2021.100108","article-title":"Sensitive and quantitative detection of MHC-I displayed neoepitopes using a semiautomated workflow and TOMAHAQ mass spectrometry","volume":"20","author":"Pollock S. B.","year":"2021","unstructured":"S. B. Pollock, C. M. Rose, M. Darwish, R. Bouziat, L. Delamarre, C. Blanchette, J. R. Lill, Sensitive and quantitative detection of MHC-I displayed neoepitopes using a semiautomated workflow and TOMAHAQ mass spectrometry. Mol. Cell. Proteomics 20, 100108 (2021).","journal-title":"Mol. Cell. Proteomics"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature19330"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"Roden R. B. S.","year":"2018","unstructured":"R. B. S. Roden, P. L. Stern, Opportunities and challenges for human papillomavirus vaccination in cancer. Nat. Rev. Cancer 18, 240\u2013254 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2606"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2015.40"},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4049\/jimmunol.134.1.157","article-title":"In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2","volume":"134","author":"Lotze M. T.","year":"1985","unstructured":"M. T. Lotze, L. W. Frana, S. O. Sharrow, R. J. Robb, S. A. Rosenberg, In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J. Immunol. 134, 157\u2013166 (1985).","journal-title":"J. Immunol."},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00628"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20220-1"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11782-w"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000673"},{"key":"e_1_3_2_59_2","first-page":"e1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein C.","year":"2017","unstructured":"C. Klein, I. Waldhauer, V. G. Nicolini, A. Freimoser-Grundschober, T. Nayak, D. J. Vugts, C. Dunn, M. Bolijn, J. Benz, M. Stihle, S. Lang, M. Roemmele, T. Hofer, E. van Puijenbroek, D. Wittig, S. Moser, O. Ast, P. Brunker, I. H. Gorr, S. Neumann, M. C. de Vera Mudry, H. Hinton, F. Crameri, J. Saro, S. Evers, C. Gerdes, M. Bacac, G. van Dongen, E. Moessner, P. Umana, Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Onco. Targets Ther. 6, e1277306 (2017).","journal-title":"Onco. Targets Ther."},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179431"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13234"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24987-9"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1631"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006611"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101747"},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13550-018-0435-z","article-title":"In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET","volume":"8","author":"Pektor S.","year":"2018","unstructured":"S. Pektor, L. Hilscher, K. C. Walzer, I. Miederer, N. Bausbacher, C. Loquai, M. Schreckenberger, U. Sahin, M. Diken, M. Miederer, In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Res. 8, 80 (2018).","journal-title":"EJNMMI Res."},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9730"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-15-190"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100374"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.309"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015024"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.12.011"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0302-7"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00052-2"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.02.018"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2016-0275"}],"container-title":["Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/sciadv.aeh9215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:59:09Z","timestamp":1788544749000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/sciadv.aeh9215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":75,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2026,9,4]]}},"alternative-id":["10.1126\/sciadv.aeh9215"],"URL":"https:\/\/doi.org\/10.1126\/sciadv.aeh9215","relation":{},"ISSN":["2375-2548"],"issn-type":[{"value":"2375-2548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"2026-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eaeh9215"}}